From: Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients.
Characteristics | Dimension | Healthy volunteers | Steroid naïve asthma | Stable ICS-treated asthma | Unstable ICS- treated asthma |
---|---|---|---|---|---|
Number of patients | 12 | 14 | 16 | 16 | |
Sex | F/M | 6/6 | 8/6 | 9/7 | 10/6 |
Age | Years | 25.40 ± 5.20 | 25.00 ± 6.30 | 39.50 ± 10.70 | 45.80 ± 7.30 |
Duration of symptoms | Years | 2.71 ± 1.08+Δ | 10.80 ± 6.20*Δ | 17.06 ± 6.50*+ | |
Baseline FEV1 | % pred | 102.50 ± 9.1+Δ | 89.20 ± 12.00 Δ | 80.80 ± 7.10 Δ | 51.50 ± 11.70*+ |
FEV1/FVC ratio | % | 86 ± 7 | 73 ± 8 | 64 ± 10 | 56 ± 12 |
Serum total IgE concentration | kU/L | 61.08 ± 25.50* | 248.4 ± 202.3 | 232.5 ± 79.0 | 318.0 ± 98.0 |
Blood eosinophil count | cells/mm3 | 56 ± 22*+Δ | 212 ± 88 | 281 ± 73 | 302 ± 95 |
FENO | ppB | 15.80 ± 5.06* | 75.21 ± 37.13+ | 39.40 ± 12.50*Δ | 64.70 ± 25.04+ |
Eotaxin-1 (EBC) | pg/ml | 6.24 ± 0.70*+Δ | 9.70 ± 1.70Δ | 10.45 ± 2.00Δ | 17.97 ± 3.60*+ |
ECP (serum) | μg/l | 3.87 ± 0.81* | 13.21 ± 4.56 | 12.80 ± 3.50 Δ | 21.90 ± 8.40*+ |
ICS | μg/day | 359 ± 128 | 1078 ± 269 | ||
Positive SPT | |||||
mite/cat/moulds | 14/2/3 | 14/4/4 | 15/4/6 |